Showing results for Meetings News

February 16, 2018

ORLANDO, Fla. – Nine key studies featuring research on survivorship care will be presented at the 2018 Cancer Survivorship Symposium, taking place February 16-17 at the Hyatt Regency Grand Cypress in Orlando, Florida. These select abstracts discuss new insights for the care of patients after cancer treatment, including issues of cost, patient engagement, exercise, late effects of cancer, and insomnia

February 12, 2018

ALEXANDRIA, Va. – A pilot study of cancer survivors ages 11-15 suggests that a web-based, interactive intervention that provides rewards for exercising can motivate kids to stay physically active. Moderate to vigorous physical activity increased by an average of nearly 5 minutes a week in the group that used the intervention and decreased by an average of over 24 minutes in the control group. These findings will be presented at the upcoming 2018 Cancer Survivorship Symposium in Orlando, Florida.

February 12, 2018

ALEXANDRIA, Va. – Cancer care guidelines recommend that cancer survivors who experience sexual dysfunction after cancer treatment use therapeutic aids to help improve their sexual health. However, a new study of 25 leading cancer centers found that 87% of the centers reported having no sexual aids available on site for men, and 72% reported having no aids for women. These findings will be presented at the upcoming 2018 Cancer Survivorship Symposium in Orlando, Florida.

February 12, 2018

ALEXANDRIA, Va. – A new study suggests that a large percentage of adolescents and young adults (AYAs) who have been treated for cancer do not seek follow-up care after their primary treatment ends, despite its importance for long-term health. AYA cancer survivors are at increased risk for heart problems, infertility, and secondary cancers from cancer treatment.

February 12, 2018

ALEXANDRIA, Va. – New findings from a clinical trial of women with breast cancer suggest that guided exercise with a physical therapist after lymph node dissection helps women regain their range of arm motion more quickly. These findings will be presented at the upcoming 2018 Cancer Survivorship Symposium in Orlando, Florida.

February 12, 2018

ALEXANDRIA, Va. – A follow-up study to a randomized clinical trial reveals that exercising during adjuvant (post-surgery) chemotherapy helps people engage in more physical activity years later. Four years later, people with breast or colon cancer who had participated in an 18-week exercise program while receiving chemotherapy engaged in physical activity 142 minutes per week or 20 minutes per day more, on average, than those who did not participate in the exercise program. Researchers will present their findings at the upcoming 2018 Cancer Survivorship Symposium in Orlando, Florida.

February 8, 2018
SAN FRANCISCO - Eight noteworthy studies exploring key research in the treatment of genitourinary cancers will be presented at the 2018 Genitourinary Cancers Symposium, taking place February 8-10 at the Moscone West Building in San Francisco, California. These abstracts investigate several approaches to the treatment and management of prostate, kidney, and bladder cancers. 
February 5, 2018

ALEXANDRIA, Va. – In a phase III clinical trial of people with previously untreated metastatic renal cell cancer (mRCC), combining immunotherapy atezolizumab with targeted therapy bevacizumab delayed cancer growth by about three months longer than sunitinib, another targeted therapy. The benefit of atezolizumab plus bevacizumab was greater for patients with PD-L1-positive tumors. These findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San Francisco, California.

February 5, 2018

ALEXANDRIA, Va. – Findings from the phase III placebo-controlled SPARTAN trial suggest that apalutamide is an effective treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk for developing metastatic disease, and for whom no approved treatments exist. Men who received apalutamide had a 72% lower risk of metastasis or death than those who received placebo. 

February 5, 2018

ALEXANDRIA, Va. – A new analysis of the ongoing STAMPEDE clinical trial found that adding the chemotherapy drug docetaxel to hormone therapy for advanced prostate cancer improves quality of life and lowers the need for subsequent therapy. Docetaxel was also found to be cost-effective. These findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San Francisco, California.

January 29, 2018

ALEXANDRIA, Va. – Co-sponsors of the 2018 Cancer Survivorship Symposium announced today five abstracts that will be highlighted in the meeting’s official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Monday, February 12, 2018, from 12:00 noon – 1:30 p.m. ET.

The following studies will be featured during the presscast:

January 22, 2018

SAN FRANCISCO – Eight noteworthy studies exploring the implications of immuno-oncology for patient care will be presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. The meeting will take place January 25-27 at the San Francisco Marriott Marquis in San Francisco, California. These notable abstracts discuss the efficacy of immunotherapy in rare cancers, biomarkers to predict which patients will benefit most, and managing the adverse effects of immune-based treatments.

January 16, 2018

ALEXANDRIA, Va. – A new study has found that a test that identifies circulating tumor cells (CTCs) present in the bloodstream can detect colorectal cancer at an early stage, with accuracy ranging from 84 to 88%. Most prior studies using CTCs have been able to detect late-stage colorectal cancer, and this study is one of the first clinical studies to show that CTCs can be useful for detecting early, more treatable stages of the cancer. These findings will be presented at the upcoming 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, California.

January 12, 2018

ALEXANDRIA, Va. – Co-sponsors of the 2018 Genitourinary Cancers Symposium announced today four abstracts to be highlighted in the meeting’s official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Monday, February 5, 2018, from 12:00 noon – 1:30 p.m. ET.